Fig 3.

Survival from diagnosis of patients in first complete remission/very good partial remission with unsuspected relapse detected by monitoring that included iodine-123–metaiodobenzylguanidine (¹²³I-MIBG) scans (blue line), unsuspected relapse detected by monitoring that included iodine-131–metaiodobenzylguanidine (¹³¹I-MIBG) scans (gray line), and symptomatic relapse (gold line; P = .002).